JP2024525222A - Ｅｒｋ１／２阻害剤併用療法 - Google Patents

Ｅｒｋ１／２阻害剤併用療法 Download PDF

Info

Publication number
JP2024525222A
JP2024525222A JP2023579857A JP2023579857A JP2024525222A JP 2024525222 A JP2024525222 A JP 2024525222A JP 2023579857 A JP2023579857 A JP 2023579857A JP 2023579857 A JP2023579857 A JP 2023579857A JP 2024525222 A JP2024525222 A JP 2024525222A
Authority
JP
Japan
Prior art keywords
cancer
compound
administered
pharma
nsclc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579857A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022271935A5 (https=
JP2024525222A5 (https=
Inventor
グプタ，サンディープ
デニス，ルイス
レディ，サンジーバ
コーコラン，ライアン，ビー．
Original Assignee
アサナ バイオサイエンシーズ，エルエルシー
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アサナ バイオサイエンシーズ，エルエルシー, ザ ジェネラル ホスピタル コーポレイション filed Critical アサナ バイオサイエンシーズ，エルエルシー
Publication of JP2024525222A publication Critical patent/JP2024525222A/ja
Publication of JPWO2022271935A5 publication Critical patent/JPWO2022271935A5/ja
Publication of JP2024525222A5 publication Critical patent/JP2024525222A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023579857A 2021-06-24 2022-06-23 Ｅｒｋ１／２阻害剤併用療法 Pending JP2024525222A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214764P 2021-06-24 2021-06-24
US63/214,764 2021-06-24
PCT/US2022/034702 WO2022271935A1 (en) 2021-06-24 2022-06-23 Erk1/2 inhibitor combination therapy

Publications (3)

Publication Number Publication Date
JP2024525222A true JP2024525222A (ja) 2024-07-10
JPWO2022271935A5 JPWO2022271935A5 (https=) 2025-06-24
JP2024525222A5 JP2024525222A5 (https=) 2025-06-24

Family

ID=84544892

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579857A Pending JP2024525222A (ja) 2021-06-24 2022-06-23 Ｅｒｋ１／２阻害剤併用療法

Country Status (8)

Country Link
US (1) US20240316046A1 (https=)
EP (1) EP4358967A4 (https=)
JP (1) JP2024525222A (https=)
KR (1) KR20240055721A (https=)
CN (1) CN117957001A (https=)
AU (1) AU2022300355A1 (https=)
CA (1) CA3223692A1 (https=)
WO (1) WO2022271935A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200071765A1 (en) * 2016-01-19 2020-03-05 The General Hospital Corporation Cancer treatments and methods of selecting same
JP7234418B2 (ja) * 2019-05-16 2023-03-07 イーライ リリー アンド カンパニー Ｂｒａｆｖ６００ｅ大腸癌の治療に使用するためのｅｒｋ１／２阻害剤と、ｂｒａｆ阻害剤およびｅｇｆｒ阻害剤との三重組み合わせ
CA3158910A1 (en) * 2019-10-28 2021-05-06 Asana Biosciences, Llc Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2

Also Published As

Publication number Publication date
CN117957001A (zh) 2024-04-30
US20240316046A1 (en) 2024-09-26
EP4358967A4 (en) 2025-06-25
EP4358967A1 (en) 2024-05-01
AU2022300355A1 (en) 2024-01-18
CA3223692A1 (en) 2022-12-29
WO2022271935A1 (en) 2022-12-29
KR20240055721A (ko) 2024-04-29

Similar Documents

Publication Publication Date Title
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
US20240285625A1 (en) Erk1/2 and kras g12c inhibitors combination therapy
US20240207269A1 (en) Uses of heterocyclic inhibitors of erk1/2
US10548894B2 (en) Combination therapy
TW201410247A (zh) 醫藥組合
JP2016106092A (ja) 組合せ
JP2024525222A (ja) Ｅｒｋ１／２阻害剤併用療法
US20250120978A1 (en) Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy
JP5890310B2 (ja) 組合せ
US20240307392A1 (en) Erk1/2 and egfr inhibitors combination therapy
CN117858725A (zh) Erk1/2和egfr抑制剂组合疗法
WO2022271939A1 (en) Erk1/2 and cdk4/6 inhibitors combination therapy
CN117940132A (zh) Erk1/2和kras g12c抑制剂组合疗法
CN117897158A (zh) Erk1/2和shp2抑制剂组合疗法
EA040191B1 (ru) Комбинированная терапия
HK1214135B (en) Combination therapy comprising a b-raf inhibitor and a second inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250616